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Mutations in the leucine-rich repeat kinase 2 (LRRK2)-encoding gene are
the most common cause of monogenic Parkinson’s disease. The identiﬁca-
tion of LRRK2 polymorphisms associated with increased risk for sporadic
Parkinson’s disease, as well as the observation that LRRK2-Parkinson’s
disease has a pathological phenotype that is almost indistinguishable from
the sporadic form of disease, suggested LRRK2 as the culprit to provide
understanding for both familial and sporadic Parkinson’s disease cases.
LRRK2 is a large protein with both GTPase and kinase functions. Muta-
tions segregating with Parkinson’s disease reside within the enzymatic core
of LRRK2, suggesting that modiﬁcation of its activity impacts greatly on
disease onset and progression. Although progress has been made since its
discovery in 2004, there is still much to be understood regarding LRRK20s
physiological and neurotoxic properties. Unsurprisingly, given the presence
of multiple enzymatic domains, LRRK2 has been associated with a diverse
set of cellular functions and signalling pathways including mitochondrial
function, vesicle trafﬁcking together with endocytosis, retromer complex
modulation and autophagy. This review discusses the state of current
knowledge on the role of LRRK2 in health and disease with discussion of
potential substrates of phosphorylation and functional partners with partic-
ular emphasis on signalling mechanisms. In addition, the use of immune
cells in LRRK2 research and the role of oxidative stress as a regulator of
LRRK2 activity and cellular function are also discussed.
Introduction
Parkinson’s disease (PD) is an insidious and progres-
sive neurodegenerative disease, affecting around 1–2%
of the population over the age of 65 [1]. The vast
majority of PD is sporadic in origin, with only 5–10%
being familial [2]; because age is the most signiﬁcant
risk factor for the development of the disease, and
with an ever-increasing life span in the western world,
disease prevalence is likely to increase. Current treat-
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slowing disease progression. Moreover, it has been
estimated that by the time that motor symptoms
emerge, 50–70% of substantia nigra dopaminergic
neurons have already degenerated [3]; damage which is
currently irreversible. It is clear that there is a direct
need to increase understanding of PD aetiology and
the molecular mechanisms of pathogenesis in order to
achieve early diagnosis and identify potential neuro-
protective therapies.
Mutations in the gene encoding for leucine-rich
repeat kinase 2 (LRRK2) are the most frequent cause
of familial PD [4]. LRRK2-PD has an almost indistin-
guishable clinico-pathological phenotype from sporadic
PD regarding age of onset, the presence of Lewy bodies
(although a minority of cases have been reported with-
out Lewy bodies) [5] and responsiveness to dopamine
replacement therapy. These observations, paired with
the identiﬁcation of LRRK2 polymorphisms associated
with increased lifetime risk for developing sporadic PD
[6], suggested that LRRK2 may provide a deep under-
standing of the molecular mechanisms of PD. The exact
physiological role of LRRK2 is still unknown, although
it has been implicated in many cellular functions. In the
effort to tackle PD, there is a compelling need for a
profound understanding of LRRK2 functions, as well
as a description of the signalling pathways in which
LRRK2 may be involved in diverse cell types, the iden-
tiﬁcation of regulators of LRRK2 activity, binding
partners and phosphorylation targets.
LRRK2 genetics, protein domain
structure; kinase and GTPase
activities
In 2004, LRRK2 was identiﬁed as the gene responsible
for PD inheritance associated with the PARK8 locus
[7,8] and was found to be comprised of 51 exons, giv-
ing rise to a large (268 kDa) protein. Subsequently,
many variants in LRRK2 primary structure have been
identiﬁed, including dominant mutations segregating
with familial PD that also occur in sporadic PD and
in cancer [9], together with polymorphisms at the
LRRK2 locus that increase the lifetime risk for the
development of sporadic PD, but also inﬂammatory
bowel disorder and leprosy [4,10,11].
LRRK2 is a multidomain protein encompassing two
enzymatic functions at its core. The GTPase domain,
comprising of Ras of complex protein (ROC) termi-
nating with a spacer domain called the C-terminal of
the Roc-domain (COR), is immediately followed by
the kinase domain, belonging to the serine/threonine
kinases. This enzymatic core is surrounded by protein–
protein interaction domains comprising the armadillo,
ankyrin and leucine-rich repeat (LRR) domains at the
LRRK2 N terminus [12]. The LRRK2 C terminus
harbours the WD40 domain, which is deemed essential
for protein folding, thus controlling LRRK2 function
and kinase activity [13] (Fig. 1). Interestingly, the
dominant, pathogenic mutations described up to date,
occur within the enzymatic core of LRRK2 (Fig. 1),
suggesting that modiﬁcation of LRRK2 activity
greatly impacts PD onset and progression. The similar-
ity in PD phenotype and age of onset between homo-
zygous and heterozygous mutation carriers suggests
that pathogenic mutations might act by conferring a
toxic function on LRRK2 [14,15].
In the overall LRRK2-PD population, the G2019S
mutation is the most frequent pathogenic mutation [4].
Its occurrence differs among groups; the G2019S muta-
tion is rare in Asia, although it is relatively frequent in
Southern Europe, reaching a maximum frequency in
Ashkenazi Jewish (10–30% of PD patients are G2019S
carriers) [16] and North African Berber populations
(35–40% of PD patients are G2019S carriers) [17]. The
penetrance of the G2019S-LRRK2 mutation appears to
have a clear age-dependent effect and varies from
around 50% at age 50, to ~ 74% at age 79 [16];
although some patients do not manifest any clinical fea-
tures even in their 80s [18]. The G2019S mutation occurs
in the kinase domain of LRRK2, leading to an increase
in kinase activity [19]. Cellular toxicity, in both the
absence and presence of oxidative stress, and the forma-
tion of inclusion bodies were observed when overex-
pressing G2019S-LRRK2 in cell lines and primary
neuronal cultures [20,21]. These results, and the fact
that genetic inactivation of LRRK2 kinase activity
showed a protective effect against such a toxic pheno-
type, suggest that an alteration in LRRK2 kinase activ-
ity is potentially involved in the neurotoxic and
pathogenic mechanisms of LRRK2-PD. A second
mutation in the kinase domain (I2020T) was isolated in
the Japanese family in which the PARK8 locus was ﬁrst
described as being associated with PD [22]. The effect of
this mutation on LRRK2 kinase activity remains con-
troversial [23–25] and, even with a conﬁrmed increase in
kinase activity, it would not be as striking as that
reported for G2019S-LRRK2 under the same experi-
mental conditions [26]. Nevertheless, I2020T-LRRK2
has been shown to induce toxicity in overexpressing
models [19,27]. Combined analysis of LRRK2 toxicity
when carrying the G2019S or I2020T mutation suggests
that an increase in LRRK2 kinase activity is sufﬁcient
per se, but not essential to trigger neurotoxicity.
The kinase function of LRRK2 is of particular
interest, especially to pharmacologists, because kinases
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kinase domain is thought to assume a typical kinase
fold, in which an N-terminal and a C-terminal sub-
domain can be identiﬁed, with the active site sitting in
the cleft between the two. The activation loop, thought
to be situated in the C terminus of the kinase domain
[28], possesses a DYG motif. In some proteins, this
motif undergoes conformational changes that may be
related to kinase activity regulation [29]. Interestingly,
the G2019S mutation is situated within this segment of
the activation loop and it has been speculated that the
glycine residue here imparts conformational ﬂexibility
[30]; therefore, replacement of the glycine with a serine
residue may alter LRRK2 dynamics.
The R1441C, R1441G and R1441H mutations are
located in the GTPase domain of LRRK2; the
R1441G mutation is especially frequent in the Basque
population where it accounts for > 40% of familial
PD cases [31]. Finally, the Y1699C mutation lies
within the spacer domain, between the GTPase and
kinase domains, and is responsible for one of the larg-
est PD pedigrees in the UK with 25 affected subjects
over four generations [32]. The R1441C/G/H muta-
tions showed decreased GTP hydrolysis [33,34], as did
the Y1699C mutation [35]. Their impact on the kinase
function of LRRK2 is still debatable [26]; even if an
increase in kinase activity is present, it is recorded as a
moderate effect in comparison with G2019S-LRRK2.
R1441C, R1441G and Y1699C LRRK2 have been
associated with cellular toxicity [27,36] thus reinforcing
the idea that kinase activity is not the only culprit
for LRRK2-induced neurotoxicity. Collectively, this
suggests that the pathobiology of LRRK2 is likely
to involve the entire enzymatic core, its activity, its
folding and potentially its interactions with functional
partners.
The presence of a double enzymatic core within the
LRRK2 protein suggests that these two functions
might inﬂuence each other’s activities. Autophospho-
rylation of speciﬁc residues (Fig. 1) within the ROC
domain has been found to modulate GTP binding [37]
and it has been suggested that LRRK2 GTPase activ-
ity is regulated by its kinase activity. However, this
should be viewed with some caution; autophosphory-
lation has been observed predominantly in in vitro
assays as opposed to cellular systems. Moreover, if
GTPase activity were regulated solely by autophos-
phorylation, it would be logical to assume that muta-
tions within the kinase domain would subsequently
alter GTP binding/hydrolysis. The hydrolysis of GTP
to GDP has been shown to be altered in cell cultures
expressing mutations in the GTPase domain
[33,35,38]. However, mutations such as G2019S, which
occur in the kinase domain of the protein, do not dis-
rupt this [39]. Recently, LRRK2 kinase activity was
shown to be dependent on GTP binding to the ROC
domain [40]. In addition, ARHGEF7, the rho guanine
nucleotide exchange factor, was identiﬁed as an inter-
actor of LRRK2 that could inﬂuence GTP hydrolysis
activity [41], whereas the guanine exchange nuclear
factor GAP (ArfGAP1) markedly reduced GTP
hydrolysis and promoted the kinase activity of
LRRK2 in vitro [42]. Furthermore, using a systems
biology approach, Dusonchet et al. [43] identiﬁed reg-
ulator of G-protein signalling 2 (RGS2) as an interac-
tor able to regulate LRRK2 kinase and GTPase
activities in vitro in a synergistic manner. Clearly, the
enzyme activities of LRRK2 undergo intramolecular
Fig. 1. LRRK2 domian structure, pathogenic mutations, constitutive and autophosphorylation sites important for understanding LRRK2
function and dysfunction. Pathogenic mutations and susceptibility polymorphisms are shown in red, constitutive phosphorylation in green
and a selection of autophosphorylation sites shown in black. The blue curved arrows depicts intramolecular regulation of kinase activity by
other LRRK2 domians; IkappaB and casein kinase 1 alpha (shown in yellow) phosphorylate and PP1 alpha dephosphorylates (shown in fawn)
LRRK2 at S910/S935 sites.
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LRRK2 interactors.
In addition to the known pathogenic mutations,
there are a number of coding variants within the
LRRK2 gene which are very rare, and some of these
are also present in controls (see Paisan-Ruiz et al. [18]
for a detailed review on LRRK2 genetics). Among
these, the coding variants G2385R in the WD40
domain and R1628P in the COR domain act as com-
mon PD risk factors among Asian populations [44–
46]. The G2385R variant essentially doubles the life-
time risk of getting PD [47]. It has been shown that
the C-terminally truncated constructs that include the
WD40 domain impacts on LRRK2 kinase activity,
and a G2385R substitution resulted in ~ 50% loss of
kinase activity [13]. Interestingly, a combined G2019S/
G2385R construct harboured kinase activity similar to
WT-LRRK2 protein, suggesting that these mutations
were in fact opposing each other’s functions [13]. This
is further suggestive of a complex interplay of intramo-
lecular interactions within the LRRK2 molecule that is
likely to reﬂect on cellular functions of LRRK2. The
rare N1437H polymorphism has been found in Scandi-
navian families [48,49], but the lack of detailed genetic
data makes the pathogenic prediction uncertain. How-
ever, overexpression of the construct in HEK293 cells
led to increased phosphorylation at Ser1292 [50]. The
genome-wide association study by Ross et al. [47]
showed the LRRK2 locus to be an independent risk
factor for sporadic PD. This important ﬁnding,
together with a similar phenotypic spectrum of
LRRK2 patients compared with sporadic cases [51],
has fuelled the hypothesis that LRRK2 might also
play a role in the pathogenesis of sporadic PD.
One ﬁnal remark should be on LRRK20s closest
paralogue LRRK1. Despite rare variants in LRRK1
having been proposed to segregate with PD, there is
no genetic support for the causal involvement of
LRRK1 in disease [52]. LRRK1 displays a similar
domain organization as LRRK2 [53], however, it has
been observed that they have speciﬁc and independent
interactors and are implicated in unique cellular path-
ways [54]. Unfortunately, because of its nonpathogenic
relevance, LRRK1 is not a subject of intense study like
LRRK2. There are also limited tools developed to
study LRRK1; antibodies are not as reliable as those
validated for LRRK2, LRRK1 knockout mice [55]
and double LRRK2/LRRK1 knockout mice are avail-
able (Jackson laboratories) but they have not been
extensively studied and there are currently no LRRK1
kinase inhibitors. However, given the close similarity
between LRRK1 and LRRK2 and the apparent
absence of involvement of LRRK1 in PD, it would be
extremely interesting to analyse functional differences




Research efforts focussed towards ﬁnding molecular
substrates of LRRK2 phosphorylation have proven
difﬁcult and at the moment, the only recognized target
for LRRK2 kinase activity is LRRK2 itself. LRRK2
has been found to autophosphorylate > 20 serine and
threonine residues in vitro [37,50,56–61]. The majority
of the autophosphorylation sites reside in the ROC
domain, with only a few in the COR and kinase
domains (Fig. 1). The physiological relevance of these
phosphorylation sites is still not clear; some of them
have failed to be detected in vivo. In the cellular con-
text, autophosphorylation was observed at T1410 [61]
and at Ser1292 and this was proposed as a potential
measure of LRRK2 kinase activity [50].
Immediately prior to the LRRK2 ROC domain,
there is a cluster of serine residues – Ser910, Ser935,
Ser955 and Ser973 [60,62–64] (Fig. 1), which are con-
stitutively phosphorylated; however, they are not auto-
phosphorylation sites. Phosphorylation of these
residues is affected by LRRK2 mutations in the ROC/
COR/kinase domains, by LRRK2 kinase inhibition
and also by extrinsic stressors [62,65,66]; they are,
therefore, used as indirect measures of LRRK2 kinase
activity. Dephosphorylation of Ser910/Ser935 affects
14-3-3 binding and impacts on downstream signalling
[65,66]. The Ikappa B family of kinases has been
shown to phosphorylate LRRK2 at Ser910/Ser935 [67]
and more recently, casein kinase 1 alpha was proposed
as the kinase that phosphorylates LRRK2 at these
sites [68]. However, Protein phosphatase 1A (PPIA)
dephosphorylated LRRK2 at Ser910/Ser935 which was
reversed using calyculin A [69], a PP1A inhibitor. Fur-
ther conﬁrmation of PP1A as the phosphatase for
LRRK2 constitutive phosphorylation was shown when
calyculin A prevented dephosphorylation of LRRK2
at Ser910/Ser935 as a consequence of arsenite-induced
oxidative stress [66]. Finding kinases and phosphatases
modulating LRRK2 function in a variety of brain cell
types and under different cellular contexts will be an
important avenue of LRRK2 research that should aid
in our understanding of the pathobiology of LRRK2.
Signalling pathways through LRRK2
The presence of active kinase and GTPase domains
surrounded by protein–protein interaction motifs,
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ling pathways. Indeed, over the past decade, many dif-
ferent signal transduction cascades have been
associated with LRRK2 (Fig. 2).
The mitogen-activated protein kinase pathways
(MAPK) were among the ﬁrst to be investigated as
potentially related to LRRK2. MAPK pathways are
composed of three layers of proteins able to activate
each other in a cascade. At the top layer is a kinase
identiﬁed as MAP3K that is able to phosphorylate
and activate a MAP2K in the second layer, which con-
sequently activates the ﬁnal MAPK, thus inducing a
change in transcription. LRRK2 was able to bind to
and phosphorylate MAP2K, -3, -4, -6 and potentially -
7 in vitro [70,71]. Furthermore, a G2019S-LRRK2
transgenic mouse model showed degeneration of dopa-
minergic neurons in the substantia nigra concomitant
with hyperphosphorylation of MAP2K4 [72]. Activa-
tion of MAP2K3 and MAP2K6 is stimulated by stress,
cytokines and growth factors, leading to the activation
of the downstream effector p38. Activation of
MAP2K4 and MAP2K7 is equally sensitive to stress,
cytokines and growth factors, leading to the activation
of the downstream effector JNK. JNK, and p38, are
known to control cell proliferation and differentiation,
apoptosis, inﬂammation, immune responses and the
production of cytokines [73].
Another MAPK pathway was recently associated
with LRRK2 after MAP2K1 and MAP2K2 (also
known as MEK1 and MEK2) were found to be acti-
vated by G2019S-LRRK2, leading to hyperphosphory-
lation of their effectors; ERK1 and ERK2. The
alteration of this MAPK pathway was considered
responsible for the G2019S-LRRK2 mediated increase
in basal autophagy [74].
The Wingless signalling pathway (Wnt) is responsi-
ble for the activation of the transcription factor b-cate-
nin, and is able to regulate nearly 400 genes [73]
involved in cell growth, apoptosis, immune functions
and inﬂammation, synaptogenesis during embryonic
development and synaptic maintenance in adulthood;
alterations in the Wnt pathway have been linked to a
loss of synapses during Alzheimer’s disease [75]. First,
the ROC–COR domain of LRRK2 was shown to
interact with Dishevelled proteins 1, -2 and -3 (DVL1–
3), key components of the Wnt pathway, whereas
LRRK2 pathogenic mutations were sufﬁcient to alter
this binding [76]. This association has been further
characterized and LRRK2 is now hypothesized to
have a role interacting with DVL1–3 and other pro-
teins in the canonical Wnt cascade (LRP6 and BDC),
thus enhancing the transduction of the Wnt signal
[77].
It is interesting to note that LRRK2 is also involved
in cancer signalling pathways. Thus, LRRK2 has been
associated with MET signalling pathways in papillary
renal and thyroid carcinomas; in particular, LRRK2
knockdown was shown to reduce tumour proliferation
with concomitant increase in cell death, and reduction
of MET signalling through the effectors target of rapa-
mycin (TOR) and signal transducer and activator of
transcription 3 (STAT3) [78]. In this respect, MET is
an oncogene tyrosine kinase receptor that controls
multiple pathways involved in cell proliferation and
Fig. 2. Implication of LRRK2 in signalling pathways. The cartoon depicts multiple signalling pathways that have been associated with LRRK2
function in physiology and/or disease. Signalling pathways are sometimes interconnected and they coordinate the control over multiple
cellular activities as reported in the red boxes.
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ety of downstream effectors, among which are b-cate-
nin and ERK, thus linking MET with the Wnt and
MAPK pathways [79].
LRRK2 has been suggested to modulate nicotinic
adenine acid dinucleotide phosphate receptors, with
consequent activation of a calcium signalling cascade
(mediated by CaMKKb) that would eventually acti-
vate adenosine monophosphate-activated protein
kinase (AMPK) to coordinate different cellular func-
tions related to nutrient homeostasis and energetic bal-
ance [80]. The CaMKKb/AMPK pathway for
induction of autophagy is sensitive to inhibition by
endoplasmic reticulum-located Bcl-2 [81]; intriguingly,
it has recently been proposed that G2019S-LRRK2
may be able to bind to and phosphorylate Bcl-2, with
a consequent reduction of the mitochondrial mem-
brane potential, thus stimulating mitophagy [82].
Human LRRK2 and its Drosophila orthologue were
shown to be able to phosphorylate eukaryotic initia-
tion transcription factor 4E binding protein (4E-BP)
[83]. 4E-BP is a downstream effector in the TOR path-
way and its dephosphorylation during nutrient depri-
vation reduces protein synthesis. However, these data
was not reproduced in mammalian cells [84]. LRRK2
control over phosphorylation of 4E-BP was not sup-
ported by analysis of sporadic or G2019S-LRRK2 PD
brains, or in LRRK2 knockdown or G2019S overex-
pressing mice [85]. It is, therefore, possible to argue
that results from in vitro assays and low-complex
model organisms may not be directly transferable to
mammalian systems. However, there are other plausi-
ble hypotheses to justify this discrepancy; there may be
speciﬁc signals needed to activate the function of
LRRK2 over 4E-BP in mammalian systems, or the
involvement of LRRK2 within this branch of the TOR
pathway may be cell speciﬁc, meaning that a cautious
selection of cell type is needed to be able to detect it.
Knockin transgenic mice expressing G2019S-
LRRK2, as well as LRRK2 knockout mice, exhibited
increased expression of mTOR in the kidneys, whereas
knockin transgenic mice expressing a kinase inactive
form of LRRK2 showed the opposite [86]. In the same
publication, changes were also described, in the kid-
neys, for 4E-BP1 and for protein kinase B (Akt),
another hub protein that shares functions with mTOR
in the control of the cell metabolism. However, the tis-
sue speciﬁcity of these alterations and the complexity
of results coming from different genotypes, make the
physiological relevance of these results difﬁcult to con-
textualize without further investigations.
Another study in Drosophila proposed that LRRK2
associates with Drosophila Argonaute-1 (dAgo1) and
human Argonaute-2 (hAgo2), thus modulating the
RNA-induced silencing complex [87]. A recent ﬁnding
suggested a component of the protein synthesis path-
way, the ribosomal small subunit s15, to be phosphor-
ylated by LRRK2 and sustain cell toxicity in both
Drosophila model and human neurons [88]. Interest-
ingly, the same study reported that s15 was hyper-
phosphorylated in ribosomal fractions from a small
number of G2019S brains compared with controls [88],
although this would need further veriﬁcation using a
larger cohort. Another study performed by micro-
array-based protein interaction technology and afﬁnity
puriﬁcation coupled by tandem mass spectrometry iso-
lated, among many other positive hits, few ribosomal
proteins as possible LRRK2 interaction partners [54],
even though they were not selected to be carried on to
validation. Similarly, previous immunoprecipitation
tandem mass spectrometry isolated, but did not vali-
date, translation initiation factor 2C1 and 2C2 as pos-
sible LRRK2 interactors [89]. Overall, these reports
suggest a possible control of LRRK2 over protein syn-
thesis; but nonetheless, these will need further func-
tional conﬁrmation in mammalian systems for a true
physiological function.
A recent study in LRRK2 knockout mice showed
that LRRK2 interacts with the PKARIIb subunit of
the protein kinase A holoenzyme regulating its locali-
zation. Aberrant localization of protein kinase A in
knockout mice increased coﬁlin and glutamate recep-
tor 1 (GluR1) phosphorylation, thus interfering with
synaptogenesis and dopamine signalling through the
dopamine receptor Drd1 [90].
A ﬁnal remark should be for the 14-3-3 proteins
that have been demonstrated to be LRRK2 interaction
partners involved in the regulation of LRRK2 cellular
localization [62]. 14-3-3 proteins are able to interact
with a plethora of target proteins, thus supporting the
function of many different signalling cascades;
amongst which are the AMPK [91] and the TOR [92]
pathways.
An interesting variety of signalling pathways have
been associated with LRRK2 thus far from various
reports (see Fig. 2), however, these data have to be
considered cautiously because there is still incomplete
agreement regarding their relevance. Reproducibility
problems arise by the use of different cellular models,
different species and sometimes in vitro kinase assays
that have been difﬁcult to replicate under expression
of physiological levels of LRRK2. However, the
intriguing idea behind this plethora of possible
LRRK2-modulated signalling pathways is that
LRRK2 might play more than one role depending on
the cell type in which it is expressed. Moreover, the
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cause a gain of novel functions, thus implicating
LRRK2 in pathology pathways that may not be rele-
vant under physiological conditions. This may support
the existence of different functions for LRRK2 in PD,
cancer and immune disorders, and it suggests caution
in extrapolating general information from different
model systems and from experiments involving the use
of mutant LRRK2.
LRRK2 and cytoskeleton
Abnormalities in neurite outgrowth and branching
were among the earliest observed LRRK2 cellular phe-
notypes [93–95]. It was initially proposed that the
source of such morphological changes could be a con-
sequence of apoptotic processes [94]; however, further
studies provided evidence for an association of
LRRK2 with tubulin/actin, thus suggesting that such
morphological changes may be consequences of
LRRK2-modulation of cytoskeletal dynamics. The
GTPase domain of LRRK2 was shown to pull-down
a/b tubulin from cell lysates [96]; LRRK2 was copre-
cipitated with b tubulin from wild-type mouse brain
and recombinant LRRK2 has been proposed to phos-
phorylate b tubulin in vitro [97]; a high-throughput
screening to decipher LRRK2 interactome revealed
proteins of the actin family and from the actin-regula-
tory network to be LRRK2 interactors with LRRK2
able to affect actin polymerization in vitro [98], and
ﬁnally, LRRK2 carrying pathogenic mutations was
found to decorate microtubules in cell models [99].
Further work has demonstrated that the interaction
between LRRK2 and the cytoskeleton components is
not just for the purpose of localization; LRRK2 was
found to be able to modulate cytoskeletal dynamics.
Disassembly of actin ﬁlaments in a process mediated
by the GTPase Rac1, was observed in cell lines after
LRRK2 knockdown or expression of mutant LRRK2
[100]. In neuronal cells from R1441G-LRRK2 trans-
genic mice, as well as in G2019S-LRRK2 ﬁbroblasts,
LRRK2 sensitized the actin cytoskeleton to depoly-
merizing agents [101]. LRRK2 was shown to be able
to phosphorylate moesin [25], a member of the ezrin/
radixin/moesin (ERM) protein family involved in regu-
lation of actin and microtubule structure; G2019S-
LRRK2 transgenic and LRRK2 knockout mice were
shown to have alterations in the pool of ﬁlamentous
actin in the ﬁlopodia as a consequence of alterations
of ERM proteins phosphorylation [95].
R1441C and Y1699C-LRRK2, but not G2019S or
wild-type LRRK2, were found to decorate nonacety-
lated microtubules in cell lines and to alter axonal
transport in rat neuronal cultures and in Drosophila
with a mechanism dependent on microtubules acetyla-
tion [102]. LRRK2 binding to tubulin was associated
with modulation of microtubule stability and acetyla-
tion [103]. The stabilization of microtubules by
LRRK2 may be mediated by LRRK20s interaction
with microtubule-associated protein tau, because it has
been demonstrated that LRRK2 is capable of phos-
phorylating tau in the presence of tubulin, thus alter-
ing microtubule–tau binding dynamics [104].
Furthermore, introduction of human LRRK2 into a
mouse model of tauopathy increased tau phosphoryla-
tion at various epitopes and changed its aggregation
properties [105].
It is difﬁcult to ﬁnd a reoccurring theme with LRRK2
ﬁndings, and make unique sense of the results obtained
in experiments performed with wild-type LRRK2,
mutated forms of LRRK2 and LRRK2 knockout. It is,
therefore, difﬁcult to determine whether the regulation
of cytoskeleton dynamics is a normal LRRK2 physio-
logical feature, if it is altered during disease, thus con-
tributing to pathogenesis, or if it is a function that gains
relevance during disease only. Moreover, it is still not
clear whether mutations in the GTPase or kinase
domain of LRRK2 affect the regulation of cytoskeleton
dynamics to the same extent.
However, a putative function of LRRK2 in cyto-
skeletal dynamics is intriguing, not only because it
could elegantly recapitulate morphological alterations
observed in cellular models of LRRK2, but also
because it lends to the possibility that LRRK2 may be
involved in development and even govern different
functions in development and adult life.
LRRK2 and autophagy
Autophagy was initially associated with LRRK2 when
blocking macroautophagy through the knockdown of
essential autophagy proteins (Atg7 and Atg8) was sufﬁ-
cient to attenuate the toxicity of overexpressed G2019S-
LRRK2 in SHSY5Y cells [106]. A following report
localized LRRK2 to autophagic vesicles and multivesic-
ular bodies, whereas the knockdown of endogenous
LRRK2 was found to be sufﬁcient to induce macro-
autophagy in HEK293 cells [107]. Numerous studies
have followed this route of investigation, analysing the
role of LRRK2 in autophagy. However, different
approaches and model systems have been used to study
LRRK2 and it is still not known whether the role of
LRRK2 may be different throughout cell lines. The
effect of LRRK2 overexpression may be different with
respect to studies at endogenous levels, and it is not
known whether the two enzymatic domains within
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Thus, although there is evidence implicating LRRK2 in
autophagy, the extant literature is not sufﬁcient, and at
times controversial, in describing the molecular mecha-
nisms through which this association happens. First,
LRRK2 has been found to be a degradation substrate
of chaperone-mediated autophagy. Overexpression of
G2019S or WT-LRRK2 was able to reduce the payload
of chaperone-mediated autophagy, indicating that an
accumulation of a-synuclein, and misfolded proteins in
general, as seen in PD, may be a partial consequence of
a LRRK2-mediated alteration of cellular proteolytic
pathways [108]. LRRK2 kinase inhibitors and knock-
down [109–111], as well as LRRK2 overexpression in
cell models [80], were able to modify the macroauto-
phagic ﬂux in vitro; however, it is still debatable
whether LRRK2 possesses a positive or negative regu-
latory role in the control of macroautophagy and if the
role of LRRK2 resides within the initiation or the clear-
ance steps. This open debate has been further empha-
sized by the study of LRRK2 knockout animal models.
Even though the brain of LRRK2 knockout mice did
not recapitulate the pathological hallmarks of PD, a
biphasic alteration in macroautophagy has been
observed in the kidneys, with enhanced autophagy at
young ages and reduced autophagy at old ages [112].
The use of human ﬁbroblasts carrying LRRK2 patho-
genic mutations has conﬁrmed an alteration in auto-
phagy with reports suggesting an increase in basal
macroautophagy in G2019S carriers [113], or an
impaired response to starvation-induced macroauto-
phagy across mutations in the LRRK2 catalytic core
(G2019S, Y1699C and R1441G) [114]. The use of
induced Pluripotent Stem cell (iPSC)-derived, human
dopaminergic neurons carrying G2019S-LRRK2 has
conﬁrmed a reduction in macroautophagy in compari-
son with healthy controls [115]; but again, details of the
molecular mechanism underlying this are still ambigu-
ous. The recent identiﬁcation of potential interactors of
LRRK2 such as Rab7L1, GAK, BAG5, Rab32 and en-
dophilin A (EndoA) [116–118], and the description of
an autophagy/lysosomal phenotype that can be cor-
rected by Rab9 in mutant Drosophila [119] suggest that
the study of LRRK2 in autophagy should probably be
considered with a much wider prospective, taking into
account a possible involvement of LRRK2 in vesicles
dynamics in general.
LRRK2 function in vesicle dynamics
and retromer function
Recent accruing evidence suggests a role for LRRK2 in
vesicle dynamics and retromer function. LRRK2 was
found to be associated with membranous structures
and vesicles in the mammalian brain [120] and enriched
in the Golgi complex [42,94] at the extent that mice
with wild-type and G2019S-LRRK2 overexpression
presented fragmentation of the Golgi complex [121].
LRRK2 has been described as regulating synaptic
endocytosis via association with Rab5b; siRNA knock-
down of LRRK2 markedly reduced synaptic vesicle
endocytosis [122], which was reversed by the introduc-
tion of Rab5B. In mammalian cells, interaction was
seen between LRRK2 and the dynamin GTPase super-
family [123] involved in membrane scission during
clathrin-associated endocytosis. In Drosophila, LRRK2
was shown to phosphorylate EndoA, decreasing En-
doA afﬁnity for membranes and affecting EndoA-
dependent membrane tubulation. The G2019S muta-
tion impeded synaptic endocytosis [116] that was
restored by pharmacological inhibition of LRRK2
kinase activity in G2019S overexpressing ﬂies. Knock-
out of EndoA led to neurodegeneration [73], thus link-
ing LRRK2-associated defects to PD. These results
were recently further validated in mammalian cells in
which LRRK2 was described as being able to phos-
phorylate neuronal-speciﬁc EndoA1 [124].
LRRK2 has been proposed to participate in the
control of synaptic vesicle exocytosis by phosphorylat-
ing Snapin, and thus regulating soluble NSF attach-
ment protein receptor (SNARE) complex functionality
and late endosomal transport [125]. Alterations in the
amount of ready releasable vesicles have been
described in cell models overexpressing G2019S-
LRRK2 [126]. LRRK2 silencing in primary cortical
neurons showed altered vesicle-recycling dynamics and
increased vesicle kinetics, suggesting a role for LRRK2
in the control of vesicle pools within the presynaptic
bouton [127]. Furthermore, inhibition of LRRK2
kinase activity was proven to reduce neurotransmitter
release, thus impacting on presynaptic functionality
(103). Studies in LRRK2 knockout rats proposed
LRRK2 to take part in the control of vesicles exocyto-
sis in lung cells [128].
Recently, LRRK2 has been described as colocalizing
with Sec16A, a protein involved in the formation of
the endoplasmic reticulum exit site. Loss of LRRK2
led to a reduction in protein transport to the dendritic
spine with a consequent reduction in glutamate recep-
tors onto the synapse surface [129].
Two interesting studies by MacLeod et al. [130] and
Beilina et al. [118] showed a genetic interaction
between LRRK2 and Rab7L1; a genetic risk factor for
sporadic PD. Expression of G2019S-LRRK2 in pri-
mary neurons induced lysosomal swelling and accumu-
lation of a component of the retromer complex; the
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phate receptor is normally recycled between endolyso-
somes and the Golgi apparatus [131]. The sorting
defect was rescued by the overexpression of the retro-
mer component VPS35, as well as the overexpression
of Rab7L1 [130]. Subsequently, Rab7 was found in
complex with LRRK2 to cooperatively promote clear-
ance of Golgi-derived vesicles through the autophagy–
lysosomal system. The pathogenic mutations, G2019S,
R1441C and Y1699C enhanced Golgi clearance, but
the hypothesis-testing mutations that decrease GTP
binding, the T1348N, or the kinase-inactive K1906M,
did not sustain Golgi clearance, suggesting that both
kinase and GTPase activities are required for main-
taining this cellular process [118]. Overexpression of
VPS35 exhibited protective effects in mutant LRRK2
Drosophila [132]; it is of interest to note that mutations
in the VPS35 encoding gene have been identiﬁed in
PD families [133,134], further implicating the disrup-
tion of retromer mediated protein sorting as poten-
tially leading to PD.
Many LRRK2 transgenic models have been created
in an attempt to model PD. Although none have alter-
ations resembling PD and the vast majority show no
signs of neurodegeneration either, some exhibit a vari-
ety of synaptic alterations [135] such as altered striatal
dopamine release and/or uptake [136], impairment of
dopamine signalling through D2 receptors [137],
impaired dopamine reuptake [138], alteration of gluta-
matergic transmission [139], impaired synaptic vesicles
endocytosis with ultrastructural abnormalities in stria-
tal neurons [124] and decreased extracellular dopamine
levels in the presence of unaltered synthesis, storage
and uptake [140]. These ﬁndings may be seen as a con-
ﬁrmation of a putative LRRK2 function at the syn-
apses; however, it is very difﬁcult to harmonize
different results coming from different models and
combine them to eventually draw an exhaustive picture
of the molecular mechanism supported by LRRK2. At
the moment, we can only conﬁdently state that the
bulk of all these studies suggest that LRRK2 may be
associated with a complex array of cellular functions
involving vesicle dynamics, trans-Golgi networks and
autophagy/lysosomal homeostasis. The intriguing
hypothesis is that the synergism of all these membrane
dynamics may be controlled by LRRK2 and may be
at the molecular base of PD neurodegeneration.
LRRK2, reactive oxygen species and
mitochondria
LRRK20s putative association with mitochondria sug-
gests that it might play a role in mitochondrial
dysfunction driving PD pathogenesis. Indeed, ﬁbro-
blasts from PD patients carrying the G2019S mutation
showed abnormal mitochondrial morphology [141].
Similarly, wild-type LRRK2 overexpression in SH-
SY5Y cells caused mitochondrial fragmentation, which
was further exaggerated by the R1441C and G2019S
mutations [142]. In G2019S transgenic mice, ultrastruc-
ture examination showed an accumulation of damaged
mitochondria, consistent with altered mitophagy in
aged mice [143]. In a double-transgenic mouse express-
ing G2019S-LRRK2 and A53T a-synuclein, structural
and functional abnormalities within the brain mito-
chondria suggested LRRK2 to induce a mitochondrial
phenotype [121]. Overexpression of G2019S-LRRK2 in
SH-SY5Y cells caused mitochondrial uncoupling, lead-
ing to reduced membrane potential and increased oxy-
gen consumption [144]. Primary mouse cortical
neurons expressing either G2019S or R1441C-LRRK2
demonstrated increased mitophagy associated with
altered calcium levels [145]. Although human iPSC-
derived neurons carrying G2019S or R1441C-LRRK2
showed normal mitochondrial electron transport chain,
they showed increased vulnerability to chemical stres-
sors and disrupted mitochondrial movement [146].
LRRK2 overexpression caused the recruitment of dyn-
amin-like protein 1 (DLP1) protein to the mitochon-
dria [142]. Similarly, coexpression of DLP1 and
LRRK2 induced increased oxidative stress, DLP1 relo-
cation to the mitochondria and promoted mitochon-
dria clearance [147]. Finally, inhibition of DRP1 was
able to rescue mitochondrial fragmentation in both
G2019S expressing HEK cells and G2019S-LRRK2 ﬁ-
broblasts [148]. These observations suggest that
LRRK2 might be responsible for mitochondria
homeostasis, possibly via DLP1-dependent, mitochon-
drial quality control. However, it remains to be deter-
mined whether this truly acts as a primary pathogenic
event in LRRK2-PD, or if mitochondrial damage hap-
pens just as a secondary consequence of LRRK2-
induced toxicity.
The same causative hierarchy is yet to be determined
for the association of LRRK2 with reactive oxygen
species (ROS). Elevated ROS has been implicated as a
pathological feature of PD; WT-LRRK2 may be neu-
roprotective, attenuating H2O2-induced cell-death in
HEK293 and SH-SY5Y cells [149], whereas iPS cells
carrying the G2019S mutation were found to be more
sensitive to H2O2 exposure with increased caspase 3
activation and cell death [150]. Similarly, mitochon-
drial dysfunction has been linked to increased ROS
production in LRRK2 mutant cells [147].
Several mechanisms have been proposed to control
the link between increased vulnerability to ROS and
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dependent interactions were shown between LRRK2
and two of its hypothetical substrates, DLP1 [147] and
peroxiredoxin 3 (PRDX3) [151]. However, increased
vulnerability to ROS was also described after overex-
pression of mutations outside the kinase domain as
well as with kinase dead mutations in Caenorhabd-
itis elegans [152], again suggesting that the molecular
function of LRRK2 is likely to be governed by a deli-
cate balance between kinase and GTPase activities.
More recently, studies from our laboratory have
shown that oxidative stress caused by arsenite led to
altered biochemical properties of LRRK2 protein.
Arsenite-induced stress caused LRRK2 self-associa-
tion, inhibited its kinase activity, abrogated the GTP
binding and translocated LRRK2 into centrosomes
[66]. In the context of exogenous stress and LRRK2
properties, it will be important to study other relevant
PD stressors in different cellular phenotypes.
LRRK2 and the immune system
Despite LRRK2 having ubiquitous expression, sub-
stantial levels of LRRK2 protein and mRNA are pres-
ent in peripheral blood mononuclear cells, lymph
nodes, spleen [153] and primary microglia [154]. There
is no deﬁnitive description of LRRK2 function in
immune cell lineages and how this may contribute to
disease pathogenesis. It has been proposed that within
the immune system, LRRK2 may be involved in the
activation and maturation of immune cells [155], in
controlling the radical burst against pathogens in mac-
rophages [156], and in modulating neuroinﬂammation
through cytokine signalling [157,158]. A more detailed
link between LRRK2 and neuroinﬂammation in PD
has been discussed recently by Greggio and colleagues
[159].
The manifestation of these very speciﬁc functions of
LRRK2 within the immune system opens up the
intriguing hypothesis that LRRK2 may play different
roles within different cell types and tissues. This sce-
nario could be explained only by the presence of
molecular mechanisms allowing the same LRRK2 pro-
tein to behave differently in different tissues; those
mechanisms may be based on cell-type-speciﬁc
LRRK2 differential splicing, or on tissue-speciﬁc
expression of LRRK2 activators, substrates and part-
ners. Little is known about LRRK2 splicing and it
may be reasonable to suppose that different cell types
express different LRRK2 isoforms potentially involved
in different cellular functions. The ﬁrst study per-
formed in mice showed indeed a differential expression
of two splicing variants of LRRK2 in primary
neurons, astrocytes and microglia [160], but more
investigations are required.
Different cell lineages may express different LRRK2
partners able to speciﬁcally regulate LRRK2 levels
and phosphorylation; features that are supposed to be
linked with LRRK2 activation/repression. This
assumption was demonstrated by the observation that
LRRK2 expression and activity can be modulated via
immune-cell-speciﬁc signalling pathways (Fig. 3). For
example, LRRK2 expression can be induced in periph-
eral blood mononuclear cells by interferon-c [156,161];
or in monocytes after triggering their maturation to
dendritic cells and macrophages [155]. It was also dem-
onstrated that in a macrophagic cell line (RAW264.7)
and a microglial cell line (BV2), stimulation of toll-like
receptors 2 and 4 (TLR2, TLR4) was able to increase
phosphorylation of LRRK2 and induce its recruitment
to membranes [67,109]. Finally, toll-like receptor 4
stimulation was able to increase LRRK2 expression
and phosphorylation in primary rat microglia [158].
LRRK2 was described as a negative regulator of
nuclear factor of activated T cells (NFAT), a protein
involved in transcriptional regulation in T cells, mac-
rophages, dendritic cells and neutrophils [162]; rein-
forcing the hypothesis that LRRK2 may have a
precise role in the immune system because of the pecu-
liar interaction partners through which it can exert tis-
sue-speciﬁc functions. The pathological implications of
these observations are intriguing in two ways. First,
this enforces the relevance of astrocytes and microglia
Fig. 3. Implication of LRRK2 in immune-speciﬁc functions. The
cartoon summarizes the LRRK2-speciﬁc events that have been
described to occur in cells from the immune system.
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croglia and monocytes, as well as increased cytokine
levels, were reported in PD brains [26]. Second, a puta-
tive role of LRRK2 in the regulation of the immune
response may justify the genetic association of LRRK2
with the susceptibility to inﬂammatory bowel disorder
[10] and leprosy [11] other than with PD.
LRRK2 kinase inhibition: therapeutic
potential
The fact that LRRK2-PD has an almost indistinguish-
able pathological phenotype from sporadic PD and the
presence of a druggable kinase activity within LRRK2
were sufﬁcient reasons for researchers to look at this
protein as a potential target for a neuroprotective
treatment in PD. Most notably, the development of
selective pharmacological inhibitors of LRRK2 kinase
activity is an active area of research with at least six
potential LRRK2 inhibitors described in the literature
and many leading pharmaceutical companies working
on LRRK2 research programmes (see Ref. [163] for a
review). Although some of the earlier inhibitors had
rather limited use because of their nonselective effects
in cells and their inability to cross the blood–brain
barrier [164,165], the development of LRRK2-IN-1
[166] provided the ﬁrst step towards a pharmacological
tool to deﬁne the biological role of LRRK2, at least in
cell models. On the ﬂip side, LRRK2-IN-1 is not brain
penetrant and also has inhibitory effects on ERK5
[161], a critical enzyme and therefore ruling out its use-
fulness in clinical settings. Furthermore, it has recently
been demonstrated that LRRK2-IN-1 exhibits signiﬁ-
cant off-target effects, independently of LRRK2,
including the inhibition of tumour necrosis fac-
tor alpha in astrocytes and increased neurite branching
and length in neurons [167]; perceived pathways of
LRRK2 pathology. Not only does this highlight the
problematic use of LRRK2-IN-1 when investigating
LRRK2 function, but also negative off-target effects
in a therapeutic context.
Following the initial screening for LRRK2 inhibitor
compounds, more brain-penetrant LRRK2-speciﬁc
inhibitors were developed soon thereafter. The com-
pound HG-10-102-01(4) showed selective inhibition of
WT and G2019S-LRRK2 at micromolar concentra-
tions in mouse brain and also inhibited Ser910/Ser935
phosphorylation [168]. The compound GSK2578215A
[169] was highly selective for LRRK2 kinase inhibition
when compared with more than 450 other kinases
tested. However, both these compounds have limited
pharmacokinetic properties that exclude these from
testing in clinical trials in humans.
Based on the structure of the HG-10-102-01(4) com-
pound, two further compounds were developed
recently; the GNE-0877 and GNE-9605 [170]. Both
these compounds demonstrated high selectivity,
potency, brain penetrance and good metabolic clear-
ance and stability when tested in vivo in rat models
expressing human LRRK2 (see Ref. [171] for a
review). The improved pharmacokinetic proﬁle sup-
ported the hypothesis that these compounds can be
safely tested in higher order animals and could poten-
tially be entered into the preliminary stages of drug
screening.
Clearly, the developments in identifying LRRK2
kinase inhibitors and a potential to treat PD have now
entered an exciting phase but should be viewed with
cautious optimism. A recent report demonstrated
abnormal lung, kidney and liver pathology in LRRK2
knockout rats compared with rats expressing physio-
logical levels of LRRK2 [172]. Crohn’s T2397M-
mutant LRRK2 patients have reportedly lower levels
of LRRK2 protein activity within their immune cells
[162], suggesting that one harmful side effect of a com-
plete inhibition of LRRK2 as a treatment for PD
could be the development of intestinal-immune dis-
eases. What would be necessary now is the investiga-
tion of LRRK2 inhibitors in higher order mammalian
models including their long-term effects on the
immune cells and peripheral organs in order to assess
safety [173]. The efﬁcacy of such a therapy will also
need to be demonstrated, and conﬁrmation of the
physical substrates of LRRK2 will aid in designing
alternative activity assays for such inhibitors. As well,
a general consensus of a model for LRRK2-mediated
pathology will need to be agreed upon in order for a
validation criteria to be established [173]. Importantly,
for clinical use, the long-term beneﬁts of LRRK2
inhibitor treatment should outweigh the advantages of
the already existing symptomatic treatments for PD
[174]. In this endeavour, it will be important to
broaden the search for LRRK2 inhibition to include
domains outside of the kinase domain [175, 176].
Concluding remarks
It is evident that there is still much to be understood
about the LRRK2 protein regarding both its physio-
logical and neurotoxic properties. A large variety of
functions have been associated with LRRK2, both in
terms of its physiological and cellular roles, and its
pathological role during neurodegeneration (Fig. 4).
These constitute an intricate network of LRRK2 puta-
tive functions making it central to two recent bioinfor-
matics articles that have analysed LRRK2 interactome
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repositories of cellular pathways [177,178]. Instead of
a clarifying mechanism of LRRK2-PD, this wide range
of implicated functions makes interpreting LRRK20s
role in disease even more challenging. Many questions
are still unanswered. This is, in part, due to the com-
plex protein structural domains of LRRK2, as well as
the variety of models used in LRRK2 research. What
needs to be resolved now is the ability to distinguish
between LRRK2 physiological functions and those
that are acquired during pathology, and to discrimi-
nate between primary and secondary pathophysiologi-
cal events.
It is still unknown whether LRRK2 may interpret
different roles in different cell types, thus giving origin
to cell-speciﬁc phenotypes; in light of this, LRRK2
functions may be tissue speciﬁc, thus giving an expla-
nation for the plethora of activities described up to
now in diverse model systems (Fig. 4). Analysis of
LRRK2 in different cell types is of extreme interest, as
is the investigation of different LRRK2 isoforms in
different brain regions, as recently shown by Trabzuni
et al. [179] in control brains. This, together with fur-
ther studies of LRRK2-related biology associated with
ROS and PD related toxins, phosphatases and kinases
that modulate LRRK2 biology, should lead to
increased understanding on LRRK2 function and dys-
function.
It will be crucial for future research on LRRK2 to
consider the early events in neurodegeneration, as
LRRK2 genetic penetrance varies between 30% and
80% depending on age. Although the loss of dopami-
nergic neurons is a key pathological characteristic of
PD, it is preceded by many other dysregulations,
which occur prior to the development of motor symp-
toms. It is the mechanism of LRRK2 associated with
these events that needs to be uncovered. For example,
LRRK2 has been associated with Wnt signalling path-
ways [76], which are essential for the acute regulation
of synaptic function; a function that is dysregulated in
the premotor symptom stages of rodent models of PD
[180]. From this prospective, the involvement of
LRRK2 in Wnt signalling is an exciting possibility
that may give a reason for the alteration in gene
expression, as well as disruption of vesicle trafﬁcking
[181], which are implicated in PD. Another interesting
connection is between LRRK2 and the autophagy/
lysosomal/Golgi network, because alteration of the
proteolytic balance within the cell may be the reason
for the build-up of toxic aggregates of amyloidogenic
a-synuclein, as implicated in PD. Indeed, the majority
of LRRK2 mutation cases show an abnormal accu-
mulation of a-synuclein-positive Lewy bodies [182],
although it is unclear which a-synuclein species is
more relevant in G2019S pathology [183]. Identifying
signalling molecules that regulate the normal and
Fig. 4. Implication of LRRK2 in cellular functions. The cartoon represents the cellular processes (red boxes) that have been associated with
LRRK2 function in physiology and/or disease. The data are from a multitude of experiments run by laboratories across the world over the
past decade and are based on different model systems and experimental approaches. It is not possible to describe a hierarchy among these
processes, or score them based on reliability. More investigations are needed to determine which of these processes are directly controlled
by LRRK2 and which appear to be LRRK2 regulated or whether they are just consequences of other LRRK2 primary functions. It remains to
be determined if all of these functions co-occur in a single cell type or whether LRRK2 orchestrate different, speciﬁc functions in different
cell types.
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unmet need for developing novel therapies and the
choice of the most relevant disease models will be criti-
cal in this endeavour.
Finally, it is important that all progress in LRRK2
research is interpreted carefully. The development of
LRRK2 kinase inhibitors gives us cause for optimism
for potential treatment for PD, but clearly the effects
of inhibiting kinase activity should be gauged in the
context of the entire LRRK2 protein.
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